In Malaysia, where dengue has long been woven into the fabric of daily life, a vaccine capable of offering protection has existed for two years — yet for many families, it remains as distant as ever. The barrier is not ignorance or reluctance, but price: more than RM400 for a full course places the vaccine firmly within the private market, accessible to those with means and invisible to those without. What unfolds here is a familiar human tension — a public health problem met with a private solution, leaving the question of who deserves protection to be answered by household income rather than
Cost barrier keeps Malaysian parents from dengue vaccination despite two years on market
Unvaccinated children remain at risk of dengue infection, hospitalization, and potential severe complications in an endemic region.